Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140744 · ClinicalTrials.gov registry record · NA
A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint
A NA study of Subjective Cognitive Impairment, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- NA
- Development phase
- 7,000
- Enrollment target
- 1
- Study location
NCT07140744 is a NA study of Subjective Cognitive Impairment that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 7,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07140744, a NA study of Subjective Cognitive Impairment, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 7,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
Conditions Studied
Interventions
- OTHER Standard of Care
- DIAGNOSTIC_TEST P-tau217
Study Locations (1)
New York
- SiteRx Virtual Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,000 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2027-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07140744
The ClinicalTrials.gov registry entry for NCT07140744 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 7,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subjective Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT07140744 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07140744 about?
NCT07140744 is a clinical study titled "A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint". The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
What is the current status of trial NCT07140744?
This trial is currently recruiting. It is a NA study. The enrollment target is 7,000 participants. The study started on 2025-08-22. Estimated completion is 2027-10.
What conditions does trial NCT07140744 study?
This clinical trial studies the following conditions: Subjective Cognitive Impairment.
What interventions are being tested in trial NCT07140744?
The interventions under investigation include: Standard of Care (OTHER), P-tau217 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07140744?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140744 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subjective Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.